Indian drugmakers weighing portfolio rejig, manufacturing realignment to survive US tariffs. Currently, Indian pharma companies face almost zero import duties in US. In 2024, India exported drugs worth around $8.73 billion to the US — about 31 percent of its total pharma exports. Dr Reddy’s sold a basket of 14 abbreviated new drug applications (ANDAs) in US, including 1 ANDA, which is pending approval to Senores Pharmaceuticals. The company’s Promoter and Managing Director Swapnil Shah told Moneycontrol that while manufacturing in US is expensive, but import tariffs may alter the equation for low volume products. The industry is seeing a portfolio rationalisation, where companies are discontinuing less profitable products and focusing on high-margin ones, he said. The U.S. government has been prioritising local manufacturers for its federal programs like Medicare and Medicaid, offering a competitive edge for companies with US-based plants, he added. The US generics’ margins of the Indian companies have improved, they are largely concentrated in top 10-20 products, a recent Citi Research report said.